GERN Shorts Rebuild Ahead of Next Week's Earnings

Geron Corporation heads into its November 4 earnings report with short sellers adding positions into a stock that has already lost nearly 9% over the past month.

Short interest has climbed sharply this week, rising 6.4% to reach 12.3% of the free float, after falling from above 18% of float in mid-September. The jump is notable: shorts had been unwinding steadily through most of October, and this week's reversal pushes the ORTEX short score to 64, its highest reading of the past two weeks. The FINRA fortnightly print put days-to-cover at 9.87, a figure that reflects how thinly traded the stock is relative to its short book. That said, the borrow market is not under pressure. Availability is ample at 456% of short interest, meaning there are roughly 4.5 shares available to lend for every one already borrowed, and the cost to borrow has drifted lower to 0.39%, down 7% on the week. Shorts can rebuild without friction.

Options traders are not reinforcing that caution. The put/call ratio is running at 0.28, almost identical to its 20-day average of 0.28 and well below the 52-week high of 0.57. The z-score is essentially flat at -0.69. That means options positioning is neither unusually defensive nor unusually bullish heading into the print: call open interest continues to dominate, which is the baseline state for this stock.

The Street is split, though the most recent analyst actions lean bearish. Goldman Sachs reinstated with a Sell rating and a $1.00 target in July 2025, and Scotiabank downgraded to Sector Perform the same month with a $1.50 target. Those sit against Needham's Buy at $4.00 (lowered from $5.00 in November 2025) and retained Overweight ratings from Barclays and Stifel, both also at $4.00. The mean price target of $4.00 implies significant upside from the current $1.15 close, but these targets are all stale, the most recent is almost a year old, and the consensus has been drifting lower at every update. The bull case rests on the EU approval of Rytelo for low-risk myelodysplastic syndrome, which opened a new commercial channel in 2026. The bear case is straightforward: revenues have been flat, and the pivotal IMpactMF trial readout for myelofibrosis has been the central catalyst the market has been waiting on. EPS momentum factor scores rank in the 97th percentile on a 30-day basis and 81st percentile over 90 days, suggesting estimates have been rising, though the absolute earnings picture remains loss-making, with EV/EBITDA deeply negative at -24.8.

The two most recent earnings events tell a volatile story. The August 2026 print produced a 9.2% one-day drop and a 5.8% five-day decline. Earlier in the same month, a separate event generated a 17.2% one-day gain. The range of outcomes is wide enough that positioning into the November 4 release carries meaningful event risk in either direction.

Among the closest correlated peers this week, IMMX fell 9.7% and MDGL dropped 5.8%, while RIGL gained 5.1% and BCRX rose 2%. The peer group is moving in multiple directions, which gives no clean read on sector sentiment for the print.

The key question heading into November 4 is whether Rytelo commercial traction has begun to translate into revenue growth, and whether management gives any updated timeline on the MF trial data that the bear case identifies as perpetually delayed.